motexafin gadolinium

Phase 3Small molecule

motexafin gadolinium is a small molecule that works as a Ribonucleoside-Diphosphate Reductase RR1 Inhibitor; Thioredoxin Reductase 1 Inhibitor.[2] It is being investigated across 23 indications, with its most advanced program in Phase 3.[1]

motexafin gadolinium is one of 563 small molecule programs targeting Glioma. It is currently in Phase 3.

Indications

Total Trials

Active Trials

562

Competitors

Pipeline

Status by Indication[3][1]

Indication

GliomaActive, not recruiting

HIV InfectionActive, not recruiting

Non-Hodgkins LymphomaActive, not recruiting

MetastasisActive, not recruiting

Kidney CancerActive, not recruiting

Lung CancerActive, not recruiting

Central Nervous System NeoplasmActive, not recruiting

LymphomaActive, not recruiting

Brain CancerUnknown

Urogenital NeoplasmActive, not recruiting

GliomaPhase 1

Active, not recruiting

HIV InfectionPhase 3

Active, not recruiting

Non-Hodgkins LymphomaPhase 2

Active, not recruiting

MetastasisPhase 3

Active, not recruiting

Kidney CancerPhase 2

Active, not recruiting

Lung CancerPhase 2

Active, not recruiting

Central Nervous System NeoplasmPhase 2

Active, not recruiting

LymphomaPhase 2

Active, not recruiting

Brain CancerPreclinical

Unknown

Urogenital NeoplasmPhase 2

Active, not recruiting

Showing 10 of 23 indications

Competition

Competitive Landscape

2828 competitors in Breast Cancer

#DrugCompanyPhaseTrials

motexafin gadolinium

PPharmacyclics LLC.

Phase 3

1 2

Tykerb

GSK

Preclinical

80 3

Avastin

BBio-Thera Solutions

Preclinical

153 4

Nolvadex

SSan Diego Pacific Oncology & Hematology Associates

Preclinical

78 5

Prolia

Amgen

Preclinical

14 6

Megace

Bristol-Myers Squibb

Preclinical

4 7

Cymbalta

Alnylam Pharmaceuticals

Preclinical

3 8

Voltaren

Novartis

Preclinical

1 9

Lupron

EEastern Cooperative Oncology Group

Preclinical

5 10

Methylthioninium Chloride

PProvepharm SAS

Preclinical

Ranked by pipeline maturity and clinical activity. Current drug highlighted in teal.

Clinical

Trials by Indication[1]

Glioblastoma Multiforme6 trials

Gadolinium Texaphyrin Plus Radiation Therapy in Treating Patients With Supratentorial Glioblastoma Multiforme

Completed·SSidney Kimmel Comprehensive Cancer Center at Johns Hopkins·Phase 1·NCT00006452·6 enrolled

Motexafin Gadolinium Plus Radiation Therapy in Treating Patients With Newly Diagnosed Glioblastoma Multiforme

Completed·JJonsson Comprehensive Cancer Center·Phase 1·NCT00003409

Radiation Therapy and Gadolinium Texaphyrin in Treating Patients With Supratentorial Glioblastoma Multiforme

Completed·NNational Cancer Institute (NCI)·Phase 1·NCT00004262·12 enrolled

Show 3 more trials

Motexafin Gadolinium Plus Radiation Therapy to the Brain in Treating Patients With Newly Diagnosed Glioblastoma Multiforme

Completed·MMemorial Sloan Kettering Cancer Center·Phase 2·NCT00022256

Motexafin Gadolinium, Temozolomide, and Radiation Therapy in Treating Patients With Newly Diagnosed Glioblastoma Multiforme or Gliosarcoma

Completed·NNational Cancer Institute (NCI)·Phase 1/2·NCT00305864·118 enrolled

Motexafin Gadolinium in Treating Patients With Glioblastoma Multiforme Who Are Undergoing Radiation Therapy to the Brain

Completed·NNational Cancer Institute (NCI)·Phase 1·NCT00032097

Non-Small Cell Lung Cancer4 trials

Trial of Motexafin Gadolinium and Pemetrexed (Alimta®) for Second Line Treatment in Patients With Non-Small Cell Lung Cancer

Terminated·PPharmacyclics LLC.·Phase 2·NCT00365183·74 enrolled

Study of the Effect on Non-small Cell Lung Cancer of the Investigational Drug Motexafin Gadolinium When Used in Combination With Docetaxel (Taxotere)

Terminated·PPharmacyclics LLC.·Phase 2·NCT00373204·50 enrolled

Chemotherapy, Radiation Therapy, and Surgery in Treating Patients With Stage IIIA Non-small Cell Lung Cancer

Completed·NNational Cancer Institute (NCI)·Phase 1·NCT00005065·12 enrolled

Show 1 more trial

A Study of Motexafin Gadolinium (MGd) in Combination With Docetaxel and Cisplatin for Treatment of Non-Small Cell Lung Cancer (NSCLC)

Completed·PPharmacyclics LLC.·Phase 1·NCT00102505·36 enrolled

Glioma4 trials

Motexafin Gadolinium With MRI-Guided Surgery in Treating Patients With High-Grade Gliomas

Completed·JJonsson Comprehensive Cancer Center·Phase 1·NCT00003410

Motexafin Gadolinium Plus Radiation Therapy in Treating Children With Newly Diagnosed Brain Stem Glioma

Completed·NNational Cancer Institute (NCI)·Phase 1·NCT00003909·24 enrolled

Temozolomide and Radiation Therapy in Treating Young Patients With Pontine Glioma

Unknown status·CChildren's Cancer and Leukaemia Group·Phase 2·NCT00514397·43 enrolled

Show 1 more trial

Motexafin Gadolinium and Radiation Therapy in Treating Young Patients With Pontine Glioma

Completed·NNational Cancer Institute (NCI)·Phase 2·NCT00387790·64 enrolled

Chronic Lymphocytic Leukemia3 trials

Study of Weekly Motexafin Gadolinium (MGd) for Patients With Chronic Lymphocytic Leukemia or Small Lymphocytic Lymphoma

Completed·PPharmacyclics LLC.·Phase 1/2·NCT00290004·35 enrolled

A Study of Motexafin Gadolinium for the Treatment of Chronic Lymphocytic Leukemia (CLL)

Terminated·PPharmacyclics LLC.·Phase 2·NCT00076401·27 enrolled

Study of Motexafin Gadolinium (MGd) in Patients With Chronic Lymphocytic Leukemia or Small Lymphocytic Lymphoma

Terminated·PPharmacyclics LLC.·Phase 2·NCT00100711·27 enrolled

Advanced Cancer2 trials

Motexafin Gadolinium and Doxorubicin in Treating Patients With Advanced Cancer

Completed·UUniversity of Wisconsin, Madison·Phase 1·NCT00036790

Study of Motexafin Gadolinium and Docetaxel for Advanced Cancer

Completed·PPharmacyclics LLC.·Phase 1·NCT00120939·25 enrolled

16 more indications

Immunotherapy1 trial

Pilot Study of MGd + High-dose MTX-Based Chemoimmunotherapy + RT for Newly Dx PCNSL

Withdrawn·NNorthwestern University·Phase 1·NCT00734773

Whole Brain Radiation1 trial

Study of Motexafin Gadolinium With Whole Brain Radiation Therapy Followed by Stereotactic Radiosurgery Boost in the Treatment of Patients With Brain Metastases

Terminated·PPharmacyclics LLC.·Phase 2·NCT00121420·45 enrolled

Breast Cancer1 trial

MRI for Detecting Cancer in Women Who Are at High Risk of Developing Breast Cancer

Completed·—·N/A·NCT00003736·200 enrolled

Radiation Therapy1 trial

Study of Neurologic Progression With Motexafin Gadolinium and Radiation Therapy (SMART)

Completed·PPharmacyclics LLC.·Phase 3·NCT00054795·550 enrolled

Lymphoma1 trial

Study of Motexafin Gadolinium for the Treatment of Non-Hodgkin's Lymphoma

Completed·PPharmacyclics LLC.·Phase 2·NCT00086034·35 enrolled

Cancer of the Pancreas1 trial

Radiation Therapy Plus Gadolinium Texaphyrin in Treating Patients With Cancer of the Pancreas That Cannot Be Removed by Surgery

Completed·SSidney Kimmel Comprehensive Cancer Center at Johns Hopkins·Phase 1·NCT00003798·45 enrolled

Lung Cancer1 trial

Study of Motexafin Gadolinium (MGd) for Second Line Treatment of Non-Small-Cell Lung Cancer

Completed·PPharmacyclics LLC.·Phase 2·NCT00129844·108 enrolled

Treatment1 trial

Study of Motexafin Gadolinium for the Treatment of Renal Cell (Kidney) Cancer

Completed·PPharmacyclics LLC.·Phase 2·NCT00134186·43 enrolled

Liver Cancer1 trial

Contrast-Enhanced CT and MRI in Diagnosing and Staging Liver Cancer Using UNOS Policy

Unknown status·—·N/A·NCT01082224·440 enrolled

Kidney Cancer1 trial

Sunitinib Before and After Surgery in Treating Patients With Stage IV Kidney Cancer

Unknown status·—·Phase 2·NCT00717587·20 enrolled

Pancreatic Cancer1 trial

Radiation Therapy in Treating Patients With Bile Duct, Gallbladder, or Pancreatic Cancer

Completed·UUniversity of Pittsburgh·Phase 1·NCT00003411

Relapsed or Refractory1 trial

Phase I/II Trial of Redox Regulation in Patients With Relapsed or Refractory CD20+ NHL

Terminated·NNorthwestern University·Phase 1/2·NCT00089284·30 enrolled

Malignant Glioma1 trial

A Study of Motexafin Gadolinium and Temozolomide for the Treatment of Malignant Gliomas

Completed·PPharmacyclics LLC.·Phase 1·NCT00080054·24 enrolled

Multiple Myeloma1 trial

A Study of Motexafin Gadolinium for the Treatment of Relapsed or Refractory Multiple Myeloma

Completed·PPharmacyclics LLC.·Phase 2·NCT00096837·25 enrolled

Advanced Head and Neck Cancer1 trial

Motexafin Gadolinium With Chemotherapy and Radiation Therapy for the Treatment of Advanced Head and Neck Cancer

Terminated·PPharmacyclics LLC.·Phase 1·NCT00080028·18 enrolled

Advanced Solid Tumors1 trial

Study of Motexafin Gadolinium and Docetaxel for Advanced Solid Tumors

Completed·PPharmacyclics LLC.·Phase 1·NCT00080041·20 enrolled

Sources

References

[1]
ClinicalTrials.gov — 35 trial records for motexafin gadolinium. U.S. National Library of Medicine, National Institutes of Health.
[2]
ChEMBL — motexafin gadolinium compound record. European Bioinformatics Institute (EMBL-EBI).
[3]
Open Targets Platform — Drug–disease associations for motexafin gadolinium. EMBL-EBI & Wellcome Sanger Institute.
[4]
SEC EDGAR — Pharmacyclics LLC. company filings. U.S. Securities and Exchange Commission.

Details

Drug Info

Quick Facts

Mechanism of Action: Ribonucleoside-Diphosphate Reductase RR1 Inhibitor; Thioredoxin Reductase 1 Inhibitor[2]
Modality: Small molecule[2]
Highest Phase: Phase 3[1]
Company: PPharmacyclics LLC.

motexafin gadolinium

Status by Indication[3][1]

Competitive Landscape

Trials by Indication[1]

Glioblastoma Multiforme6 trials

Non-Small Cell Lung Cancer4 trials

Glioma4 trials

Chronic Lymphocytic Leukemia3 trials

Advanced Cancer2 trials

Immunotherapy1 trial

Whole Brain Radiation1 trial

Breast Cancer1 trial

Radiation Therapy1 trial

Lymphoma1 trial

Cancer of the Pancreas1 trial

Lung Cancer1 trial

Treatment1 trial

Liver Cancer1 trial

Kidney Cancer1 trial

Pancreatic Cancer1 trial

Relapsed or Refractory1 trial

Malignant Glioma1 trial

Multiple Myeloma1 trial

Advanced Head and Neck Cancer1 trial

Advanced Solid Tumors1 trial

References

Drug Info

Quick Facts

Related News